The widespread use of generic drugs has been hailed as one of the most important public health developments of the twenty-first century. Today, 90 percent of the U.S. pharmaceutical market is comprised of generic drugs, the majority of which are manufactured overseas. We have been reassured by our doctors, our pharmacists and our regulators that generic drugs are identical to their brand-name counterparts, just less expensive. But is this really true? Bottle of Lies: The Inside Story of the Generic Drug Boom exposes for the first time the endemic fraud behind generic drug manufacturing -and the attendant risks for global public health.The narrative investigation interweaves the stories of a determined whistleblower, an intrepid FDA investigator and drug manufacturers determined to deceive regulators. Reported on four continents over a ten-year period, and drawing on 20,000 pages of confidential FDA documents, the book uncovers how one of the world's greatest public health innovations also became one of its most astonishing swindles. Bottle of Lies uncovers a global industry where companies routinely falsify quality data, and executives circumvent almost every principle of safe manufacturing to minimize cost and maximize profit. Meanwhile, patients unwittingly consume medicine with unpredictable and dangerous effects.